Milla Pharma's FDA Nod for Vital Drug Aims to End Chronic Shortages

WHITE BEAR LAKE, MN – July 13, 2026 – In a move poised to bring significant relief to the U.S. healthcare system, Milla Pharmaceuticals Inc., the U.S. subsidiary of Belgian generics group A.forall, has secured Abbreviated New Drug Application (ANDA) approval from the FDA. The approval is for 8.4% Sodium Bicarbonate Injection, USP, a critical medication that has been a persistent and troubling feature on the nation's drug shortage list for nearly a decade.

This regulatory green light isn't just another corporate milestone; it represents a potential turning point for hospitals and clinicians who have struggled with severe supply chain disruptions for the drug since 2017. The approval allows Milla to manufacture and distribute the vital alkalinizing agent, used to treat severe metabolic acidosis, a life-threatening condition. By entering a market valued at approximately $68 million annually, A.forall is making a strategic bet that reliability can be its most valuable asset.

A Critical Tool Returns to the Arsenal

For frontline healthcare workers, the chronic scarcity of Sodium Bicarbonate Injection has been a long-running nightmare. The drug is a cornerstone of emergency and critical care, indispensable for stabilizing patients during cardiac arrest, treating severe kidney disease, managing complications from uncontrolled diabetes, and counteracting certain drug intoxications. When the body's pH balance plummets, this injectable is often the fastest and most effective way to restore equilibrium and prevent catastrophic organ failure.

Its intermittent appearance on the FDA Drug Shortages list since 2013, and the severe disruptions that began in March 2017, have forced hospitals into a constant state of crisis management. “For years, it has been a constant source of anxiety,” explained a senior hospital pharmacist at a major metropolitan medical center. “You are rationing a life-saving drug, making difficult choices about which critically ill patient gets the standard of care. It adds immense stress on staff and introduces undeniable risk.”

This scarcity forces institutions to enact conservation protocols, seek expensive alternatives from compounding pharmacies, or use different product concentrations that increase the potential for medication errors. The approval of Milla’s generic version promises a new, stable supply line, potentially ending the need for such desperate measures and allowing clinicians to focus on patient care rather than supply logistics.

A Calculated Expansion into a Volatile Market

This FDA approval is a lynchpin in A.forall's deliberate and aggressive expansion into the U.S. generic injectables market. The Sodium Bicarbonate nod marks the tenth generic product for the company in the United States and underscores a clear focus on hospital-administered, niche products that are essential but often susceptible to supply instability.

This is the company’s second injectable approved to combat metabolic acidosis, following the launch of Tromethamine in January 2025. Since that time, Milla Pharmaceuticals has rapidly built its portfolio, adding four more products under five separate ANDAs. This momentum signals a clear intent to become a significant player in a market segment that larger manufacturers sometimes neglect.

Erik Lazarich, A.forall’s President of U.S. Operations, highlighted the strategic importance of the approval. “This product was previously reported in shortage in the US for multiple years and has had so many supply chain disruptions that we are convinced the approval and launch of Sodium Bicarbonate Injection, USP is a great tool to combat metabolic acidosis,” he commented. “We are excited to continue expanding our offering of high-quality generic injectables supply throughout and beyond the U.S. market.”

By targeting a $68 million market for a single drug, A.forall isn't chasing a blockbuster. Instead, it is executing a shrewder strategy: capturing market share by solving a persistent problem for its customers. In the world of hospital procurement, a promise of consistent supply can be more powerful than a slightly lower price point.

The Broader Economics of Generic Injectables

The recurring shortages of drugs like Sodium Bicarbonate are a symptom of deeper structural issues within the pharmaceutical industry. Many of these older, sterile injectable drugs have thin profit margins, which can disincentivize manufacturers from investing in upgrading aging facilities or maintaining redundant production capacity. When a single factory—often one of only a few in the world making the drug—experiences a quality control issue, it can trigger a cascading, system-wide shortage. Past recalls by major players for issues like particulate matter have demonstrated the fragility of this supply chain.

Against this backdrop, Milla Pharmaceuticals’ entry is a welcome development. The introduction of a new, competitive manufacturer can not only stabilize supply but also exert downward pressure on prices, aligning with the company's stated mission to reduce healthcare costs. However, Milla’s success will hinge on its ability to avoid the very pitfalls that have plagued its competitors. Maintaining impeccable manufacturing standards and a resilient supply chain will be critical to fulfilling its promise to healthcare providers.

From Regulatory Win to Bedside Reality

With FDA approval in hand, the next critical step for Milla Pharmaceuticals is execution. While the company has not announced a specific launch date, the enthusiastic tone from its leadership suggests a rapid move to commercialization. Leveraging its established distribution network—which already serves wholesalers, distributors, hospitals, and infusion clinics—will be key to ensuring the product quickly reaches the facilities that need it most.

This approval is a clear victory for A.forall's strategy, for the healthcare providers who will gain a new tool, and for the patients whose care depends on it. While the systemic problem of drug shortages will require broader solutions from regulators and the industry at large, Milla Pharmaceuticals' successful journey from prototype to profit with Sodium Bicarbonate provides a much-needed injection of both a critical medicine and renewed confidence into the U.S. healthcare system.